title: Response to high-dose ifosfamide in patients with advanced/recurrent Ewing sarcoma.
abstract: OBJECTIVE
  To determine activity and toxicity of high-dose ifosfamide (HDIFO) in recurrent or advanced Ewing sarcoma family tumors (EFT).
  
  
  METHODS
  Thirty-seven EFT patients [median age 17 years (6-45 years)] previously treated with chemotherapy regimens including standard dose ifosfamide were enrolled. HDIFO was administered for metastatic recurrent disease in 33 patients and for progression during neoadjuvant chemotherapy in 4 patients. All patients who received two courses of 15 g/m(2) ifosfamide were evaluable for radiographic response assessed according to RECIST criteria.
  
  
  RESULTS
  Transient Grade 4 neutropenia and thrombocytopenia in 97% and 54% HDIFO courses respectively and severe CNS toxicity in one patient were observed. Thirty-five patients were evaluable: 12 (34%) had complete (2) or partial (10) response, 11 (32%) had stable disease, and 12 (34%) had progression.
  
  
  CONCLUSIONS
  In patients with relapsed or advanced EFT previously treated with standard dose ifosfamide HDIFO is active and it should be considered a treatment option.
authors.affiliation: Department Musculoskeletal Oncology, Istituto Ortopedico Rizzoli, Bologna, Italy. stefano.ferrari@ior.it
authors.forename: S
authors.initials: S
authors.lastname: Ferrari
authors.forename: A Brach
authors.initials: AB
authors.lastname: del Prever
authors.forename: E
authors.initials: E
authors.lastname: Palmerini
authors.forename: E
authors.initials: E
authors.lastname: Staals
authors.forename: M
authors.initials: M
authors.lastname: Berta
authors.forename: A
authors.initials: A
authors.lastname: Balladelli
authors.forename: P
authors.initials: P
authors.lastname: Picci
authors.forename: F
authors.initials: F
authors.lastname: Fagioli
authors.forename: G
authors.initials: G
authors.lastname: Bacci
authors.forename: D
authors.initials: D
authors.lastname: Vanel
mesh_terms: D000293:Adolescent; D000328:Adult; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002648:Child; D005260:Female; D006801:Humans; D007069:Ifosfamide / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D012008:Recurrence; D012512:Sarcoma, Ewing / Q000188:drug therapy* / Q000473:pathology*
chemical_list: D000970:Antineoplastic Agents; D007069:Ifosfamide